Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Tooth Whiteners Belong In Homes; FDA Denies ADA Petition For Drug Status

This article was originally published in The Tan Sheet

Executive Summary

The American Dental Association’s 2009 petition does not support a drug designation for peroxide-containing tooth-whitening products, FDA responds. Further information is needed on formulations, mechanisms of action and safety profiles for FDA to determine whether the products meet the definition of a drug.

You may also be interested in...



FTC Review Of Colgate Optic White Claims Delays Class Action Complaint

A Colgate Optic White whitening claims class action complaint is stayed pending an FTC decision on the claims, a federal judge rules. The judge denied the Colgate's motion to dismiss on the grounds the state suit is pre-empted by FDA regulations.

FTC Review Of Colgate Optic White Claims Delays Class Action Complaint

A Colgate Optic White whitening claims class action complaint is stayed pending an FTC decision on the claims, a federal judge rules. The judge denied the Colgate's motion to dismiss on the grounds the state suit is pre-empted by FDA regulations.

P&G Defends Tooth Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth-whiteners as drugs, saying ADA members' financial interests motivated the petition

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel